Understanding the side effects of retatrutide is a key part of evaluating its research profile. The 2023 Phase 2 trial provides the most detailed published safety dataset available, covering 338 participants across five treatment groups over 48 weeks. This article summarises the adverse event findings from that data, examines what the research shows about retatrutide's fat-burning mechanism, and addresses the question of long-term safety as Phase 3 development continues.
Overview: Retatrutide Safety Profile
The side effects of retatrutide observed in the Phase 2 trial were broadly consistent with the established adverse event profile of the GLP-1 receptor agonist class. The majority of events were gastrointestinal, mild to moderate in severity, and predominantly occurred during the titration phase rather than the maintenance phase. Serious adverse events were rare and the overall discontinuation rate due to adverse events was low relative to the magnitude of effects observed.
Is retatrutide safe? Based on Phase 2 data alone, the answer is that it was well tolerated in the populations studied over 48 weeks, with no unexpected safety signals emerging. However, Phase 2 data is limited in duration and participant numbers relative to what is needed to characterise rare or long-term adverse events. Phase 3 data will provide a substantially more complete picture of retatrutide long-term side effects.
Gastrointestinal Side Effects
Nausea
Nausea was the most frequently reported adverse event across all active treatment groups. It was most prevalent during the dose escalation phase, consistent with the mechanism of action: GLP-1 receptor agonism slows gastric emptying and acts on central nausea pathways via the area postrema. At higher maintenance doses (8mg and 12mg), nausea was reported in a majority of participants at some point during treatment, but rates fell substantially once the maintenance dose was reached and sustained.
Vomiting
Vomiting occurred at lower rates than nausea but was dose-dependent. It was most common during the titration phase and was classified as mild to moderate in most cases. In the small number of instances where vomiting led to dose modification or discontinuation, this was concentrated in the first eight to twelve weeks of treatment.
Constipation and Diarrhoea
Both constipation and diarrhoea were reported, with constipation somewhat more common than diarrhoea across the active groups. These effects are again consistent with the GI motility changes associated with GLP-1 receptor engagement. Constipation was typically managed conservatively and was rarely a reason for dose modification.
Non-GI Adverse Events
Heart Rate Increase
A small but consistent increase in resting heart rate was observed across all retatrutide dose groups, in line with the known class effect of GLP-1 receptor agonists. The mean increase was modest (approximately 2 to 4 beats per minute across groups) and was not associated with any significant cardiovascular events in the Phase 2 population.
Gallbladder Events
Gallbladder-related events, including gallstones, were observed in the retatrutide groups at rates consistent with rapid weight loss. This is not a retatrutide-specific effect but rather a consequence of rapid fat mobilisation reducing cholesterol solubility in bile. Similar events have been documented with semaglutide and tirzepatide at equivalent weight loss magnitudes.
Injection Site Reactions
Injection site reactions were reported in a proportion of participants but were predominantly mild (erythema, transient discomfort) and did not require treatment discontinuation in the majority of cases.
Does Retatrutide Burn Fat?
Yes, the published data shows retatrutide produces substantial fat mass reduction. The mechanism involves three complementary pathways. GLP-1 receptor agonism reduces appetite and slows gastric emptying, reducing caloric intake. GIP receptor agonism enhances the incretin response and may additionally influence adipose tissue directly. Glucagon receptor agonism increases hepatic glucose output and raises thermogenesis, which is believed to drive higher energy expenditure compared to dual agonists.
The Phase 2 data showed mean body weight reductions up to 24.2% over 48 weeks, with a substantial proportion of this reduction coming from fat mass rather than lean mass. DEXA scans performed in a subset of participants confirmed preferential fat mass loss relative to lean body mass, though lean mass was also reduced to some extent, consistent with all significant caloric restriction scenarios.
Research-Grade Retatrutide from Clarix Peptides
HPLC-verified, 99%+ purity. Certificate of Analysis with every batch. Available in 10mg and 20mg.
Retatrutide Long-Term Side Effects
The 48-week Phase 2 window provides limited data on retatrutide long-term side effects. The adverse events observed were largely concentrated in the titration period, suggesting the compound becomes better tolerated at steady-state maintenance doses. No new safety signals emerged in the latter half of the Phase 2 observation period.
Phase 3 trials, which were ongoing as of mid-2026, will provide multi-year safety datasets across much larger populations. These trials will be informative for characterising rare events and longer-duration outcomes including cardiovascular endpoints, lean mass preservation, and effects on bone mineral density. Until that data is available, the 48-week Phase 2 results represent the best available evidence base for retatrutide's safety profile.
